Skip to main content

Table 4 Relative risks of progression within 24 months and overall death within 5 years according to clinicopathological factors and RBM3 expression in patients with Ta and T1 tumours

From: Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer

  

Risk of progression within 24 months

  

Risk of death within 5 years

  

Univariable

Multivariable

  

Univariable

Multivariable

 

n(events)

HR(95%CI)

HR(95%CI)

 

n(events)

HR(95%CI)

HR(95%CI)

Age

       

Continuous

134(19)

1.02(0.98-1.07)

1.01(0.97-1.06)

 

231(88)

1.06(1.04-1.09)

1.06(1.04-1.08)

Gender

       

Female

29(2)

1.00

1.00

 

43(12)

1.00

1.00

Male

105(17)

2.48(0.57-10.74)

1.98(0.45-8.64)

 

188(76)

0.62(0.34-1.13)

1.67(0.90-3.10)

Grade

       

Low

48(3)

1.00

1.00

 

81(19)

1.00

1.00

High

86(16)

3.24(0.94-11.12)

3.32(0.97-11.40)

 

150(69)

2.22(1.33-3.68)

1.31(0.73-2.35)

Stage

       

Ta

68(7)

1.00

1.00

 

115(35)

1.00

1.00

T1

66(12)

1.90(0.75-4.83)

1.24(0.44-3.46)

 

116(53)

0.61(0.40-0.93)

1.61(1.04-2.49)

RBM3 expression*

   

RBM3 expression*

   

High

31(1)

1.00

1.00

Positive

198(69)

1.00

1.00

Negative/Intermediate

103(18)

5.92(0.79-44.39)

6.10(0.81-45.69)

Negative

33(19)

2.00(1.21-3.33)

1.64(0.96-2.78)

  1. For PFS a dichotomised variable comparing patients with negative or intermediate RBM3 expression to those with high expression was applied. For 5 year OS, a dichotomised variable of negative versus any RBM3 expression was applied.